Abstract 335P
Background
Neoadjuvant chemotherapy (NAC) of newly diagnosed breast cancer is used to improve resectability, reduce the extent of breast and axillary surgery and improve overall survival. Accurate assessment of locoregional response to NAC is important for surgical planning. Radiological method of choice is post-treatment breast magnetic resonance imaging (MRI), which determines the rate of response according to RECIST criteria. The primary indicator of outcome of NAC is pathologic complete response (pCR). This study aimed to compare radiologic and pathologic complete response rates after neoadjuvant treatment of early breast cancer.
Methods
A retrospective study of 259 breast cancer cases who received NAC between 01.01.2020 and 31.12.2021 at University Hospital Centre Zagreb was conducted with prior Ethics Committee approval. Radiological and pathohistological characteristics of the tumor at the time of diagnosis and after neoadjuvant treatment were analyzed using the Hospital information system (BIS). Furthermore, post-neoadjuvant therapy MRI findings were correlated with the postoperative pathohistological findings. Sensitivity, specificity, accuracy, and positive predictive value of radiologic complete response (rCR) as a predictor of pCR were calculated.
Results
Complete data was available for 94.98% (246/259) of patients. In 62 (25.20%) patients, rCR was recorded, radiologic partial response (rPR) in 150 (60.98%), stable disease in 22 (8.94%), and progressive disease in 9 patients. In 78 (31.71%) patients pCR was achieved, 46 (58.97%) were also classified as rCR, while 32 (41.03%) of those showed a radiological stable disease or rPR. Out of the 62 patients with rCR, 16 (25.81%) did not achieve pCR. The sensitivity and specificity of rCR were 90.48% and 58.97%, respectively, while positive predictive value was 82.61%. The overall accuracy of breast MRI in predicting pCR was 80.49%.
Conclusions
Although the sensitivity of breast MRI in predicting pCR was high, the specificity was low with only moderate overall accuracy. Low specificity can lead to an incorrect choice of breast surgery, therefore a better method of evaluation is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Krizic, N. Dedic Plavetic, T. Silovski: Financial Interests, Personal, Research Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
233P - Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
Presenter: Marianela Bringas Beranek
Session: Poster session 02
235TiP - Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Presenter: Mary Denholm
Session: Poster session 02
236TiP - Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD
Presenter: Shingo Kitagawa
Session: Poster session 02
247P - KN026 in combination with docetaxel as neoadjuvant treatment for HER2+ early or locally advanced breast cancer (BC): A single-arm, multicenter, phase II study
Presenter: Linxiaoxi Ma
Session: Poster session 02
248P - Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial
Presenter: Francesca Ligorio
Session: Poster session 02
250P - The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer
Presenter: Luke Steventon
Session: Poster session 02
251P - Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
Presenter: Jose Angel García-Sáenz
Session: Poster session 02